Balyasny Asset Management LLC Supernus Pharmaceuticals, Inc. Transaction History

Balyasny Asset Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$25.33 - $34.25 $3.14 Million - $4.24 Million	-123,826 Reduced 83.97%	23,643 $684,000
Q1 2022 May 16, 2022	BUY	$28.51 - $32.9 $4.2 Million - $4.85 Million	147,469 New	147,469 $4.77 Million
Q3 2020 Nov 16, 2020	SELL	$20.2 - $25.05 $373,195 - $462,798	-18,475 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$17.09 - $24.89 $30,061 - $43,781	1,759 Added 10.52%	18,475 $439,000
Q1 2020 May 15, 2020	SELL	$14.45 - $24.69 $8,727 - $14,912	-604 Reduced 3.49%	16,716 $301,000
Q4 2019 Feb 14, 2020	BUY	$19.93 - $29.13 $345,187 - $504,531	17,320 New	17,320 $411,000
Q3 2018 Nov 14, 2018	SELL	$42.7 - $56.55 $171,824 - $227,557	-4,024 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$44.1 - $59.85 $60,637 - $82,293	-1,375 Reduced 25.47%	4,024 $241,000
Q1 2018 May 15, 2018	BUY	$37.15 - $46.9 $200,572 - $253,213	5,399 New	5,399 $247,000
Q4 2017 Feb 14, 2018	SELL	$36.4 - $42.6 $5.3 Million - $6.2 Million	-145,625 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$36.75 - $49.65 $5.35 Million - $7.23 Million	145,625	145,625 $5.83 Million

283

60.6M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.06B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.